Dr. Chang was on the founding management team as VP Project Management at Labrys Biologics, which was acquired by Teva Pharmaceuticals. Prior to Labrys, Dr. Chang held positions as VP Project Management and Team Leader for RANEXA® at CV Therapeutics up until its acquisition by Gilead. Before that time, Dr. Chang managed the development and registration of VIRACEPT®at Agouron Pharmaceuticals, which was subsequently acquired by Pfizer. Dr. Chang earned his Ph.D. in microbiology and immunology from the University of California, Los Angeles and B.S. with honors from the University of California, Los Angeles. He conducted his post-doctoral training at the University of California, San Francisco as a Leukemia Society of America Research Fellow.